Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Low-protein diet to enhance immunotherapy effects in cancer patients

Official title: A Pilot and Feasibility Study of a Dietary Intervention With Low-protein Meals in Cancer Patients Receiving Immunotherapies

Run by State University of New York at Buffalo · NCT05356182 · Data updated 2026-11-12

This study is testing whether a low-protein diet can help cancer patients on immunotherapy respond better to their treatment.

More Medical Oncology trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment30 (estimated)
SponsorState University of New York at Buffalo
Academic / other
Drugs / interventionsimmunotherapy
Locations1 site (Buffalo, New York)
StatusRecruiting
StartedMay 4, 2022
Main results expectedFebruary 2027
Study endsFebruary 2028
Registry record updatedApril 3, 2026
Trial IDNCT05356182 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults with solid tumor malignancies who are eligible for immunotherapy and have a life expectancy of at least six months.

Probably not a fit

Patients with an ECOG performance status of 2 or higher may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the feasibility of a low-protein diet in cancer patients undergoing immunotherapy. Participants will be randomly assigned to receive either a standard diet with approximately 20% protein or a low-protein diet containing 10% protein while receiving immune checkpoint inhibitors. The goal is to determine if the low-protein diet can improve the immune response and enhance the anticancer effects of the treatment. This is a single-center, open-label study focused on patients with solid tumor malignancies.

Why it matters

Potential benefit: If successful, this approach could improve treatment outcomes for cancer patients receiving immunotherapy.

How similar studies have gone: While dietary interventions in cancer treatment are being explored, this specific low-protein approach in conjunction with immunotherapy is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Histologically documented solid tumor malignancies which is amenable for immunotherapy treatment with immune checkpoint inhibitors (i.e. PD1, PD-L1, CTLA inhibitors) as single agents or in combination.
* Metastatic disease as evidenced by soft tissue and/or bony metastases on baseline bone scan and/or computed tomography (CT) scan of the chest, abdomen, and pelvis
* Life expectancy of at least 6 months
* Adults ≥ 18 years of age
* Adequate hematologic, renal, and liver function as evidenced by the following:

  * White blood cell (WBC) ≥ 2,500 cells/μL
  * Absolute neutrophil count (ANC) ≥ 1,000 cells/μL
  * Platelet Count ≥ 100,000 cells/μL
  * Hemoglobin (HgB) ≥ 9.0 g/dL
  * Creatinine ≤ 2.0 mg/dL
  * Total bilirubin ≤ 2 x upper limit of normal (ULN)
  * Aspartate aminotransaminase (AST, SGOT) ≤ 2.5 x ULN
  * Alanine aminotransaminase (ALT, SGPT) ≤ 2.5 x ULN

Exclusion Criteria:

* • Eastern Cooperative Oncology Group (ECOG) performance status 2 or higher

  * Treatment with any of the following medications or interventions within 28 days of registration:

    * Systemic corticosteroids; however, use of inhaled, intranasal, and topical steroids is acceptable.
    * High dose calcitriol \[1,25(OH)2VitD\] (i.e., \> 7.0 μg/week)
  * A requirement for systemic immunosuppressive therapy for any reason
  * Any infection requiring parenteral antibiotic therapy or causing fever (temperature \> 100.5°F or 38.1°C) within 1 week prior to registration
  * A known allergy, intolerance, or medical contraindication to receiving the contrast dye required for the protocol-specified CT imaging
  * Any medical intervention or other condition which, in the opinion of the Principal Investigator, could compromise adherence with study requirements or otherwise compromise the study's objectives

Where it's running

  • University at Buffalo / Great Lakes Cancer Care
    Buffalo, New York, United States
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.